IE 11 is not supported. For an optimal experience visit our site on another browser.

Conceptus(R) to Present at Two Investor Health Care Conferences in September

MOUNTAIN VIEW, Calif., Sept. 7, 2010 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure(R) procedure, the first proven non-surgical permanent birth control method available, announced today that Mark Sieczkarek, chief executive officer, is planning to present at two investor conferences in September 2010. The conferences and presentation dates and times are as follows:
/ Source: GlobeNewswire

MOUNTAIN VIEW, Calif., Sept. 7, 2010 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure(R) procedure, the first proven non-surgical permanent birth control method available, announced today that Mark Sieczkarek, chief executive officer, is planning to present at two investor conferences in September 2010. The conferences and presentation dates and times are as follows:

  • Baird 2010 Health Care Conference on Wednesday, September 15, 2010, at 2:45 p.m. Eastern time at The St. Regis, New York, NY
  • Stifel Nicolaus 2010 Healthcare Conference on Thursday, September 16, 2010, at 9:10 a.m. Eastern time at the Four Seasons, Boston, MA

Live webcasts of the presentations will be available on the company's website at . When accessing the webcasts through the Conceptus site, select "Investors" then select "Events and Presentations." Archived replays will be available for a period of 30 days.

About the Essure Procedure

The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. Essure is 99.8% effective based on four years of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay.

Three months after the Essure procedure, a doctor performs an Essure Confirmation Test to confirm that the inserts are properly placed and the fallopian tubes are fully blocked, giving the patient reliance on Essure for permanent birth control. Essure has been proven and trusted by physicians since 2002, with more than 435,000 women worldwide having undergone the Essure procedure.

About Conceptus, Inc.

Conceptus, Inc. is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Company manufactures and markets Essure permanent birth control. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.

Please visit for more information on the Essure procedure.  Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area. Information about Conceptus is available at .

© 2010 Conceptus, Inc-- All rights reserved.  Conceptus, Essure and Your Family is Complete. Your Choice is Clear are registered trademarks and service marks of Conceptus, Inc.

CC-2483  02SEP10F

CONTACT: Conceptus, Inc. Investor Relations and Public Relations Contact: Cindy Klimstra (650) 962-4032 cindy_klimstra@conceptus.com